×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Quality of Life and Caregiver Burden in PSP (NCT03638505)
clinical
1,856 words
KG: ent-clin-a767d1a0
2026-03-27
kind:clinical-trial
section:clinical-trials
state:published
psp
quality-of-life
caregiver-burden
neurodegenerative
observational
longitudinal
palliative-care
psychosocial
Contents
Quality of Life and Caregiver Burden in PSP (NCT03638505)
Knowledge Graph
Related Hypotheses (8)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Circadian Clock-Autophagy Synchronization
Score: 0.55
Temporal Decoupling via Circadian Clock Reset
Score: 0.52
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Synaptic Vesicle Tau Capture Inhibition
Score: 0.34
Show 3 more
Related Analyses (4)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Related Experiments (9)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Show 4 more
See Also (15)
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 3 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Vestibular and Balance Therapy for CBS/PSP
therapeutic · Pages share 3 hypotheses
VEGF and Angiogenesis Therapy
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
tudca-udca-neurodegeneration
therapeutic · Pages share 3 hypotheses
TRPM8 Agonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neuro
therapeutic · Pages share 3 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Transcutaneous Vagal Nerve Stimulation (tVNS) for Parki
therapeutic · Pages share 3 hypotheses
Show 10 more